N/A
N=182
Rapid HCV Treatment Access for Persons Who Use Drugs
Hepatitis C Virus Infection, Response to Therapy of
Bottom Line
View on ClinicalTrials.gov: NCT04677153 ↗Enrolled (actual)
182
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Participants Who Initiate HCV Therapy — 59; 12 Participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Test and treat plus peer mentors (Other); Usual care (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Johns Hopkins University
- Primary completion
- Feb 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participants Who Initiate HCV Therapy |
59; 12 | <0.001 sig |
| SECONDARY HCV Treatment Completion |
42; 8 | 0.762 |
| SECONDARY Sustained Virologic Response (SVR) Following Treatment by Intervention Group |
40; 8 | 0.940 |
| SECONDARY Time to HCV Treatment Initiation |
2.86; 24 | <0.001 sig |
Summary
This study is being done to compare two strategies to deliver HCV treatment to persons with hepatitis C virus (HCV) who also use drugs and are participating in an outpatient opioid treatment program (OTP). Participants will be randomized into one of two treatment groups:
1. Test and treat plus peer-mentors: This treatment group will be offered 8 weeks of glecaprevir/pibrentasvir (an FDA approved HCV treatment) within days of HCV diagnosis at the OTP. Participants in this group will receive treatment adherence support from a peer-mentor who is someone who has been cured of HCV infection.
2. Standard of care HCV treatment referral: This treatment group will be referred to an offsite HCV treatment location. This is the usual care for anyone who tests positive for HCV at the OTP who is not participating in this study.
Eligibility Criteria
Inclusion Criteria
- Ability and willingness of participant to provide written informed consent
- Men and women age ≥18 to ≤70 years at study entry
- HCV antibody positive/detectable HCV RNA
- HCV treatment naïve (no prior treatment with an approved or investigational oral Direct-Acting Antivirals (DAA) therapy
- Negative pregnancy test at screening or at the day of treatment initiation (females of childbearing potential only)
- If co-infection with Human Immunodeficiency Virus (HIV) is documented, the subject must be anti-retroviral treatment (ART) naïve with CD4 T cell count >500 cells/mm3 OR on a stable ART regimen (containing only permissible ART - Raltegravir; dolutegravir; Rilpivirine; Elvitegravir/cobicistat; Tenofovir disoproxil fumarate; Tenofovir alafenamide; Emtricitabine; Lamivudine and/or Abacavir, bictegravir)
Exclusion Criteria
- Women who are pregnant or breastfeeding, or considering becoming pregnant during the study and for 30 days after the last dose of study drug
- Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation
- Current or history of decompensated liver disease (including but not limited to encephalopathy, variceal bleeding, or ascites) prior to study entry
- History of hepatocellular carcinoma (HCC)
- Any history of active Hepatitis B or positive HBsAg test
- Platelet count < 150,000/mm3
- HCV RNA undetectable
- History of clinically significant abnormalities or co-morbidities that make the subject an unsuitable candidate for this study, in the opinion of the investigator.
- Women of childbearing potential that are not practicing at least one specified method of birth control that is effective from Study Day 1 through at least 30 days after the last dose of study drug.
- Subject is currently taking any of the following prohibited medications: red yeast rice (monacolin K), St. John's Wort, carbamazepine, dabigatran, efavirenz, phenytoin, pentobarbital, phenobarbital, primidone, rifabutin, rifampin.
- Subject is not able or willing to safely discontinue the prohibited medications or supplements listed below at least 14 days prior to the first dose of GLE/PIB: some HMG-CoA reductase inhibitors, astemizole, cisapride, terfenadine, ethinyl estradiol.
Data sourced from ClinicalTrials.gov (NCT04677153). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.